Mylan finalizes DoJ agreement, drawing line under EpiPen furore

17 August 2017
drugs_pills_tablets_big

Netherlands-based Mylan (Nasdaq: MYL) has reached an agreement with the US Department of Justice, finalizing the previously announced Medicaid drug rebate settlement of $465 million.

The firm’s shares took a beating last year amid controversy, including a congressional hearing, over the classification of EpiPen (epinephrine) products as non-innovator drugs, which led to lower rebate payments to Medicaid.

Since first revealing the settlement, Mylan has posted upbeat financial guidance for the year. The near-half billion dollar payment was booked in the company’s 2016 accounts.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics